# NICE (NCT03016871)

> Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

No report yet. It can be ordered.

- Drugs tested: nivolumab; nivolumab plus ICE
- Indication: relapsed or refractory Hodgkin lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03016871
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: City of Hope Medical Center
- Conditions: Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma
- Interventions: Carboplatin; Etoposide; Ifosfamide; Laboratory Biomarker Analysis; Nivolumab
- Enrollment: 78
- Primary outcome: Complete Response Rate by Lugano Classification
- Primary outcome: Number of Participants With Unacceptable Adverse Events

## Indexed commentary on NICE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 8
- YouTube: 2
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nice-nct03016871

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03016871", "email": "<work email>"}; the inbox owner confirms by the emailed link.